心通医疗-B(02160)公布，2025年12月19日完成发行约39.54亿股代价股份，每股发行价1.35港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 微创心通医疗科技有限公司 呈交日期： 2025年12月21日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 第一章節註釋： | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02160 | 說明 | 普通股 | | | | | | | A. 已發行股份或庫存股 ...

MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2160） 完成非常重大收購事項 及 涉及就收購目標集團 而根據特別授權發行新股份的 關連交易 目標集團的獨家財務顧問 ® 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 附註： 承董事會命 微創心通醫療科技有限公司 茲提述微創心通醫療科技有限公司（「本公司」）日期為2025年7月16日、2025年 9月29日及2025年12月15日之公告及本公司日期為2025年11月24日之通函（「通 函」）。除另有界定外，本公告所用詞彙與通函所界定者具有相同涵義。 董事會欣然宣佈，合併協議項下所有先決條件已獲達成或豁免及交易已於2025 年12月19日完成。目標公司（微創心律管理有限公司）及其附屬公司已成為本公 司的間接附屬公司。 本次合併的完成，標誌著本集團業務範圍從結構性心臟病 ...

Core Viewpoint - MicroPort Medical announced the strategic merger of its subsidiaries, MicroPort Cardiac and MicroPort Rhythm Management, to enhance the integration of its core business segments in structural heart disease and rhythm management, aiming to create a comprehensive global heart failure management platform [1][2] Group 1: Merger Details - The merger has been approved by the shareholders of MicroPort Cardiac, which will facilitate the deep integration of structural heart disease and rhythm management business segments [1] - The combined entity will address complex diagnostic and treatment needs across the entire spectrum of heart failure, from monitoring to management [1] Group 2: Product and Market Position - MicroPort Cardiac has established a leading position in the domestic market for TAVI products, with the highest implantation volume [1] - MicroPort Rhythm Management is one of the few companies globally with a complete product line for rhythm management, including pacemakers and implantable cardioverter-defibrillators (ICDs) [2] - The company has a well-established overseas channel system, contributing a significant portion of its revenue from stable markets in Europe, the Middle East, and Africa [2] Group 3: Future Plans and Innovations - The merged entity plans to develop a comprehensive management solution for heart failure, covering all stages and causes of the disease [2] - The first heart failure product, an intra-aortic balloon pump (IABP), is expected to be approved in China by 2026 [2] - The merger aims to create a three-in-one platform integrating structural heart disease, rhythm management, and heart failure management, with expectations for improved profitability through operational efficiency and continued R&D investment [2]

截至2025年12月18日收盘，心通医疗-B（02160）报收于1.15元，较前一交易日上涨1.77%，该股当日开 盘1.12元，最高1.18元，最低1.11元，成交额达258.48万元。近52周最高1.69元，最低0.63元。 根据公司当日发布的公告，微創心通醫療科技有限公司（证券代码：2160）宣布，自2025年12月22日 起，其证券简称将由"心通醫療－Ｂ"更改为"微創心通－Ｂ"。市场参与者需注意此次证券简称变更。 最新公告列表 《02160-心通醫療-B-更改證券簡稱》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Summary of the Conference Call for Xintong Medical Company Overview - Xintong Medical is acquiring MicroPort's cardiac rhythm management business for a total consideration of $680 million, with an implied enterprise value of $850 million, representing 3.9 times the projected 2024 revenue [3][4] - The acquisition aims to expand Xintong Medical's presence in the heart rate management sector and increase its overseas business share from 12%-15% to 80% [2][4] Key Points and Arguments Industry Position and Market Expansion - Post-merger, the combined entity will become the largest cardiac medical device company in Asia, competing globally with Medtronic, Abbott, and others in structural heart disease, heart rate management, and electrophysiology [2][5] - The merger is expected to generate nearly $300 million in revenue, leveraging Xintong's strengths in structural heart disease and MicroPort's expertise in sensors and active mechanical devices [4][5] Synergies and Collaborative Opportunities - Significant synergies are anticipated in revenue, manufacturing, R&D, and sales, particularly through the integration of TAVI procedures and pacemaker services [6][7] - The left atrial appendage occlusion market is projected to grow at a compound annual growth rate (CAGR) of 20%, indicating substantial growth potential [6] R&D and Product Development - The combined R&D resources will lead to the launch of several innovative products over the next five years, including next-generation left atrial appendage occluders and upgraded aortic stenosis treatment devices [2][10] - Xintong Medical has a strong foundation in structural heart disease and plans to enhance its capabilities in heart failure treatment through integrated solutions [12][15] Financial Outlook and Cost Management - The merger is expected to reduce overall debt significantly, with financial expenses projected to drop to approximately $4 million by 2026 [4][26] - R&D expenditure is anticipated to be controlled within 20% of revenue by 2025, with a goal of achieving operational profitability by 2027 [21][26] Competitive Landscape - The merged company will have a competitive edge with the smallest and longest-lasting pacemaker globally, enhancing its market position [5][10] - The integration of sales channels and marketing strategies will allow for targeted market penetration and improved pricing power [9][23] Future Growth and Market Strategy - The heart failure market is expanding due to aging populations, with 65 million global patients, including over 12 million in China [15][22] - Xintong Medical plans to develop comprehensive monitoring and management solutions for heart failure patients, utilizing advanced technologies and data analytics [19][22] Shareholder Structure Post-Merger - After the merger, MicroPort will remain the controlling shareholder with a 44% stake, while other significant shareholders include Yunfeng Capital and Hillhouse Capital [28] Potential for Future Collaborations - There is a possibility of future collaborations with pharmaceutical companies to enhance the effectiveness of heart failure monitoring and treatment solutions [29] Additional Important Insights - The merger will facilitate a more robust global presence and brand recognition, supported by a top-tier R&D center in Shanghai and a global advisory committee of experts [10][11] - The integration of existing technologies and new product lines will position the company to capture significant market share in the heart failure segment [12][22]

Core Viewpoint - MicroPort Medical announced the approval of a strategic merger between MicroPort Cardiac and MicroPort Rhythm Management, aiming to integrate their core business segments of structural heart disease and rhythm management, thereby enhancing comprehensive heart failure management solutions [2][3]. Group 1: Merger Details - The merger will enable the creation of a comprehensive management solution for heart failure, covering all causes, stages, and processes, including monitoring, diagnosis, treatment, and management [2][3]. - MicroPort Cardiac has established a leading position in the domestic market for transcatheter aortic valve implantation (TAVI) products, with the highest implantation volume [2]. - The company is advancing a new generation of innovative pipelines, including products for mitral and tricuspid valves, surgical support products, and interventricular septal reconstruction products, while also accelerating overseas market expansion [2]. Group 2: Product and Market Strategy - MicroPort Rhythm Management is one of the few companies globally with a complete product line for rhythm management, including pacemakers, implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy devices (CRT-Ds), leads, and monitoring equipment [3]. - The merged entity will leverage its product layout in structural heart disease, rhythm management, and heart failure to provide a comprehensive management solution for heart failure [3]. - The first heart failure product, an intra-aortic balloon pump (IABP), is expected to be approved in China by 2026, indicating a push towards commercializing heart failure management [3]. Group 3: Operational Synergies - Post-merger, the integration of channels, registration, and logistics systems is expected to facilitate faster market entry for structural heart disease products through the rhythm management platform [4]. - The combination of structural products with rhythm management offerings will enhance sales efficiency and marketing effectiveness in the domestic market [4].

作为全球少数拥有完整心律管理产品线的企业之一，微创心律管理（CRM）产品覆盖心脏起搏器、植 入式心脏复律除颤器（ICD）、心脏再同步治疗除颤器（CRT-D）、导线、心律管理患者监护仪及心律 不齐诊断器械等，属于心律市场和部分心衰患者所依赖的关键治疗手段。目前，CRM的海外渠道体系 完善，在欧洲、中东、非洲等地已形成稳定市场基础，贡献大部分营收，并在全球多个国家建立渠道网 络。 在收购微创心律管理后，微创心通将凭借自身在结构性心脏病、心律管理及心衰领域的产品布局，将构 建覆盖心力衰竭全病因、全阶段、全过程的综合管理方案，为不同致病因素、各疾病分期及"监测-诊 断-治疗-管理"全过程提供完整的心衰管理服务。 此次并购将推动微创医疗旗下结构性心脏病与心律管理两大核心业务板块的深度整合，面向心衰全病 因、覆盖病程全阶段的复杂诊疗需求，加速构建贯穿"监测—诊断—治疗—管理"全过程的全球化心衰专 业器械平台。 公开材料显示，我国心血管疾病现有患者人数达3.3亿，且死亡率居首位，高于肿瘤及其他疾病，且心 血管问题年轻化日趋明显。然而，与其庞大患者基数和复杂的病因结构相比，心衰器械治疗的渗透率仍 处于较低水平，现有器械应用主 ...

MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2160） 共設有五個董事委員會，下表提供各董事會成員於該等委員會中所擔任的職 務資料。 | 委員會 | 審核 | 薪酬 | 提名 | 戰略 | 商業化 | | --- | --- | --- | --- | --- | --- | | 董事 | 委員會 | 委員會 | 委員會 | 委員會 | 委員會 | | 陳國明先生 | 成員 | | | 成員 | 主席 | | Brian Chang博士 | | | 成員 | 主席 | 成員 | | 張瑞年先生 | | | | 成員 | 成員 | | Philippe Wanstok先生 | | | | 成員 | 成員 | | 鄧奧弋先生 | | | | 成員 | | | 吳夏女士 | | | | | 成員 | | 周嘉鴻先生 | 主席 | 成員 | | | | | 孫志祥女士 | 成員 | 主席 | 成員 | | | | 胡冰山博士 | | 成員 | 主席 | 成員 | | 中國上海，2 ...

格隆汇12月15日丨心通医疗-B(02160.HK)宣布，公司审核委员会、公司薪酬委员会及公司提名委员会的 组成变动如下，自2025年12月15日起生效：非执行董事兼董事会主席陈国明已获委任为审核委员会成 员，并不再担任薪酬委员会成员及提名委员会主席。独立非执行董事胡冰山已获调任为提名委员会主 席，及已获委任为薪酬委员会成员，并不再担任审核委员会成员。非执行董事Brian Chang已获委任为 提名委员会成员。 ...